Effect of Trifluoperazine in treatment of COVID-19

Evaluation of the Effect of Trifluoperazin in Treatment of Patients with Confirmed 2019 Novel Coronavirus(COVID- 19): An Open-Label Randomized Clinical Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200408046992N1

Enrollment

Registered

2020-04-14

Start date

2020-04-16

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 disease. Pneumonia due to SARS-associated coronavirus

Interventions

Intervention 1: Intervention group:35 participants in the investigational treatment group will receive trifluoprazine at a dose of 5 mg twice daily for 14 days on admission in addition to standard tre

Eligibility

Sex/Gender

All

Age

12 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with laboratory-confirmed COVID 19 infection with Real Time PCR and patients with evidence of lung involvement in CT Scan Willing to provide informed consent Age older than 12 years. Patients admitted to specialized COVID-19 ward Patients without Known severe allergy to trifluoperazine perazin and other phenothiazines such as cholorphenothiazines Patients older than age 65 years are included if they do not suffer from Dementia-Related Psychosis

Exclusion criteria

Exclusion criteria: Patient With a Liver Disorder Patients with bacterial or viral infection Pregnant women Patients with benign prostatic hyperplasia (BPH) Patients with intestinal obstruction Patients with blood disorders or bone marrow failure Coma patients and patients with central nervous system weakness

Design outcomes

Primary

Measure	Time frame
Determining the efficacy of trifluoprazine in improving the Clinical manifestations of patients with confirmed COVID-19 infection by recording the patient's clinical parameters including 7 clinical parameters of respiration number, Blood Oxigen Saturation, oxygen support, temperature, heart rate, systolic blood pressure and Awareness level, assessment of lung involvement with Chest CT-Scan, measurement of c-reactive protein on treatment days, measurement of CBC indicators and biochemical factors such as urea and creatinine. Timepoint: Check of the patient's clinical condition and blood sampling of patients on days 1-14 in the hospital and also on the 28th day after the onset of the disease. Method of measurement: Measuring CBC indicators and biochemical factors using an autoanalyzer and examining heart function using EKG,Measurement of other factors using a thermometer and blood pressure monitor and patient bedside examinations.	—

Measure

Time frame

Determining the efficacy of trifluoprazine in improving the Clinical manifestations of patients with confirmed COVID-19 infection by recording the patient's clinical parameters including 7 clinical parameters of respiration number, Blood Oxigen Saturation, oxygen support, temperature, heart rate, systolic blood pressure and Awareness level, assessment of lung involvement with Chest CT-Scan, measurement of c-reactive protein on treatment days, measurement of CBC indicators and biochemical factors such as urea and creatinine. Timepoint: Check of the patient's clinical condition and blood sampling of patients on days 1-14 in the hospital and also on the 28th day after the onset of the disease. Method of measurement: Measuring CBC indicators and biochemical factors using an autoanalyzer and examining heart function using EKG,Measurement of other factors using a thermometer and blood pressure monitor and patient bedside examinations.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMasood Ziaee

Birjand University of Medical Sciences

dr.m.ziaee@gmail.com+98 56 3238 1200

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026